The aim of this study was to investigate whether thiamine pyrophosphate (TPP) has biochemical and histological preventive effects on oxidative liver damage induced by paracetamol (APAP). Rats were divided into the following groups: healthy control (HG), APAP (AG, 1500 mg/kg, orally), thiamine pyrophosphate (TPPG, 100 mg/kg, intraperitoneally), APAP+NAC (ANAC, 100 mg/kg, intraperitoneally), APAP+TPP (ATPG) and APAP+NAC+TPP (ANTG). Oxidant, antioxidant parameters, liver function tests and histological assessment were performed between groups. Malondialdehyde levels in the AG, HG, TPPG, ANAC, ATPG and ANTG groups were 0.470 AE 0.210, 0.213 AE 0.004, 0.194 AE 0.001, 0.197 AE 0.06, 0.199 AE 0.008 and 0.173 AE 0.010 lmol/g protein, respectively. Total glutathione levels were 7.787 AE 0.395, 14.925 AE 0.932, 13.200 AE 0.984, 13.162 AE 0.486, 13.287 AE 0.787 and 13.500 AE 0.891 lM/g protein, respectively. In the AG group, marked liver damage occurred with the elevation of liver function tests and oxidative stress markers, such as malondialdehyde, myeloperoxidase and nitric oxide (p < 0.05). Biochemical results were congruent with the histological changes of oxidative damage. Compared to the AG group (p < 0.05), TPP significantly reduced oxidant parameter levels in the ATPG group and simultaneously increased the antioxidant parameter levels of catalase and glutathione. The histological changes were improved to almost normal hepatic structure. Moreover, TPP had nearly the same hepatoprotective effect as NAC, and there was statistically no additional benefit with NAC co-treatment. There was no statistically significant difference (p > 0.05) among the ANAC, ANTG and ATPG groups in terms of oxidant/ antioxidant levels. TPP proved to be as efficacious as standard therapy and may be beneficial in APAP-induced hepatotoxicity.Acetaminophen (Paracetamol, APAP) is widely used for its antipyretic and analgesic efficacy. APAP is safe and has few side effects when used at therapeutic levels. However, an overdose either in therapeutic contexts or in suicide can induce severe hepatotoxicity and acute liver failure [1,2]. Nearly 50% of all acute liver failure cases are due to APAP toxicity and carry 30% mortality [3]. In the United States, more than 100,000 cases of APAP intoxication occur annually [4]. Hepatotoxicity is the outcome of the reactive, toxic metabolite of APAP. If taken at recommended daily doses, nearly 85-90% of APAP is metabolized by glucuronidation and sulphation in the liver and subsequently excreted in the urine. In normal conditions, reactive metabolite N-acetyl-p-benzo-quinoneimine (NAPQI) is detoxified by endogenous glutathione (GSH). However, after APAP overdose, the GSH stores are depleted and sufficient NAPQI detoxification cannot be processed. This leads NAPQI to covalently bind to intracellular proteins [5]. Covalent binding is thought to be the progenitor mechanism of centrilobular hepatic necrosis, causing oxidative stress, lipid peroxidation and the depletion of protein thiols [6].In APAP hepatot...